Oscient Pharmaceuticals Corporation Provides Preliminary Revenues For Fourth Quarter And Fiscal Year 2005

WALTHAM, Mass.--(BUSINESS WIRE)--Jan. 9, 2006--Oscient Pharmaceuticals Corporation (Nasdaq: OSCI) today disclosed preliminary revenue results for the fourth quarter and fiscal year ended December 31, 2005. The Company expects to record total fourth quarter revenues of approximately $9.2 million, with approximately $8 million in revenue from its lead product, FACTIVE(R) (gemifloxacin mesylate) tablets, and the remainder primarily from the Company’s co-promotion partnership for TESTIM(R)1% testosterone gel. The Company plans to announce complete audited financial results and host a conference call with investors on March 6, 2006.

MORE ON THIS TOPIC